Comparative evaluation of bioavailability of Botulinum toxin A complexed with Tizol (titanium glycerosolvate aquacomplex) versus pure Botulinum toxin A solution for bladder mucosa: an experimental study

Introduction. For the treatment of overactive bladder syndrome (OAB), injection of botulinum toxin A (BoNT-A) has been shown to be effective. However, there is a need for a less invasive method for administering BoNT-A, which could significantly expand the treatment options for OAB.

Objective. To assess the impact of tizol on the absorption of BoNT-A by the bladder mucosa and compare it to the individual absorption of BoNT-A.

Materials & Methods. Dialysis through the mucous membrane of the сalf bladder was used as an experimental model to study changes in bioavailability of BoNT-A complexed with tisol (BoNT-A + T) and pure BoNT-A solution during in vitro experiment. After dialysis, the BoNT-A concentration in both samples was determined using a spectrophotometer. Dialysis curves were plotted according to the data obtained. Kruvchinsky equilibrium dialysis method was used to determine botulinum toxin A bioavailability. The UV spectrophotometry method was used to determine the concentration of BoNT-A in the acceptor medium by reaction of BoNT-A with Benedict's reagent.

Results. It was established that the maximum concentration of BoNT-A diffused into the acceptor medium from the blend of the test substance with tizol after nine hours. The area under the curve for dialysis of BoNT-A + T exceeds the area under the curve of pure BoNT-A by almost 20%, suggesting an improvement in the drug's bioavailability when blended with tizol.

Conclusion. Based on our experiment, it was found out that the BoNT-A + T has greater bioavailability than a solution of pure BoNT-A. However, the diffusion rate of the component mixture is sufficiently low.

1. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol. 2000;278(6):F867-F874. DOI: 10.1152/ajprenal.2000.278.6.F867

2. Jafari NV, Rohn JL. The urothelium: a multi-faceted barrier against a harsh environment. Mucosal Immunol. 2022;15(6):1127-1142. DOI: 10.1038/s41385-022-00565-0

3. Dalghi MG, Montalbetti N, Carattino MD, Apodaca G. The Urothelium: Life in a Liquid Environment. Physiol Rev. 2020;100(4):1621-1705. DOI: 10.1152/physrev.00041.2019

4. Kachar B, Liang F, Lins U, Ding M, Wu XR, Stoffler D, Aebi U, Sun TT. Three-dimensional analysis of the 16 nm urothelial plaque particle: luminal surface exposure, preferential head-to-head interaction, and hinge formation. J Mol Biol. 1999;285(2):595-608. DOI: 10.1006/jmbi.1998.2304

5. Klingler CH. Glycosaminoglycans: how much do we know about their role in the bladder? Urologia. 2016;83 Suppl 1:11-14. DOI: 10.5301/uro.5000184

6. Shashikanth N, Yeruva S, Ong MLDM, Odenwald MA, Pavlyuk R, Turner JR. Epithelial Organization: The Gut and Beyond. Compr Physiol. 2017;7(4):1497-1518. DOI: 10.1002/cphy.c170003

7. Abir-Awan M, Kitchen P, Salman MM, Conner MT, Conner AC, Bill RM. Inhibitors of Mammalian Aquaporin Water Channels. Int J Mol Sci. 2019;20(7):1589. DOI: 10.3390/ijms20071589

8. Birder LA. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol. 2005;289(3):F489-F495. DOI: 10.1152/ajprenal.00467.2004

9. Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653-680. DOI: 10.1152/physrev.00030.2012

10. Gonzalez EJ, Merrill L, Vizzard MA. Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function. Am J Physiol Regul Integr Comp Physiol. 2014;306(12):R869-R878. DOI: 10.1152/ajpregu.00030.2014

11. Burnstock G. Purinergic signalling in the lower urinary tract. Acta Physiol (Oxf). 2013;207(1):40-52. DOI: 10.1111/apha.12012

12. Li Y, Xue L, Miao Q, Mao F, Yao L, Yuan J, Qin W, Zhao Y, Sun H, Liu F, Wang H. Expression and electrophysiological characteristics of P2X3 receptors in interstitial cells of Cajal in rats with partial bladder outlet obstruction. BJU Int. 2013;111(5):843-851. DOI: 10.1111/j.1464-410X.2012.11408.x

13. Deruyver Y, Voets T, De Ridder D, Everaerts W. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? BJU Int. 2015;115(5):686-697. DOI: 10.1111/bju.12876

14. Skryma R, Prevarskaya N, Gkika D, Shuba Y. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nat Rev Urol. 2011;8(11):617-630. DOI: 10.1038/nrurol.2011.142

15. Andersson KE, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010;106(8):1114-1127. DOI: 10.1111/j.1464-410X.2010.09650.x

16. Bø K, Hilde G. Does it work in the long term?--A systematic review on pelvic floor muscle training for female stress urinary incontinence. Neurourol Urodyn. 2013;32(3):215-223. DOI: 10.1002/nau.22292

17. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87(1):165-217. DOI: 10.1152/physrev.00021.2006

18. Szallasi A. Vanilloid receptor ligands: hopes and realities for the future. Drugs Aging. 2001;18(8):561-573. DOI: 10.2165/00002512-200118080-00001

19. Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, O'Leary M, Yoshimura N, Chancellor MB. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26(4):358-363. DOI: 10.1080/10790268.2003.11753706

20. Szallasi A, Fowler CJ. After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurol. 2002;1(3):167-172. DOI: 10.1016/s1474-4422(02)00072-8

21. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105-107. DOI: 10.1126/science.1084550

22. Hicks RM. The mammalian urinary bladder: an accommodating organ. Biol Rev Camb Philos Soc. 1975;50(2):215-246. DOI: 10.1111/j.1469-185x.1975.tb01057.x

23. Berzin S.A., Zamyatin A.V., Mager V.O. Tizol distribution in the bladder wall in patients with invasive bladder cancer. Siberian journal of oncology. 2009;(S2):26-27. (In Russian).eLIBRARY ID: 12918927; EDN: KWSIKB

24. Urinary incontinence. Russian clinical guidelines. Moscow; 2021. (In Russian).

25. Guidelines EAU 2022. EAU Guidelines Office, Arnhem, The Netherlands; 2023.

26. Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124(4):794-800. DOI: 10.1097/AOG.0000000000000468

27. Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A. Nat Rev Urol. 2015;12(9):519-533. DOI: 10.1038/nrurol.2015.193

28. Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117-1124. DOI: 10.1016/j.eururo.2014.01.036

29. Hung FC, Kuo HC. Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. Toxins (Basel). 2022;14(12):838. DOI: 10.3390/toxins14120838